Alzprotect's team
Management
Dr.Philippe Verwaerde, CEO, CSO
18 years experience in the pharmaceutical industry (Organon, GlaxoWellcome and Biovitrum) and in biotechnologies (DevGen, GenFit). Co-founder of two biotech companies (Vivactis, iNovacia)
Team
Dr. Stéphane Burlet
Ph.D in Medicinal Chemistry
Project leader, outsourcing manager
Dr. Cecilia Estrella
Ph.D in Neurobiology
Project leader
Dr. Mathieu Barrier
Ph.D in Immunology
Project leader
Dr. Arnaud Parenty
Ph.D in Medicinal Chemistry and MBA
Project Leader and Business Development Assistant
Annick Wattez
Administrative assistant
Pauline Plancq, Virginie Poix and Cécile Lannoo
Ms. in biology
Board of directors
Philippe Verwaerde,
Chairman
Christian Sergheraert,
Lille 2 University Chairman
Hélène Cannard-Guillon,
Inovam
Philippe Moons,
Finorpa
Scientific Advisory Board
Pr. Thomas Bayer,
Ph.D., Professor in Molecular Psychiatry at the University Medicine of Göttingen, Department of Psychiatry. Pr. Thomas Bayer has more than 20 years of experience as scientific leader in the field of AD. Pr. Bayer coordinates the European Commission funded International Alzheimer PhD School «Neurodegeneration in Alzheimer’s disease – mechanism, consequence and therapy» (NEURAD).
Dr. Gilbert Clincke,
Ph.D., M.D, Senior Director Department Neuropsychopharmacology of Jansen Pharmaceutica. Gilbert Clincke headed research groups of more than 100 staff active in the field of drug discovery for the central nervous system. He was also the designer and responsible of the first ever full year study in Alzheimer Disease with a NCE [Sabeluzole]. He also participated to the development of several drugs [Risperdal™] for psychiatric disorders, [Sufenta™] for pain and [Reminyl™] also known as Galantamine for Alzheimer’s disease symptoms.
Dr. Jean Pierre Maffrand,
Ph.D. , former Senior Vice-President, Director of Discovery Research of Sanofi-Aventis, in charge of more than 3000 people on the 17 European and American sites. Jean Pierre Maffrand has a strong track record in the drug discovery and development including the development of major products (Ticlid® and Plavix®). He is the author or co-author of more than 194 publications and 78 patents and received numerous awards during its career.
Pr. Florence Pasquier,
M.D., Ph.D. (in cognitive neuropsychology), professor of neurology. Head of the memory clinic of Lille University Hospital (France), she is leading a research team entitled "vascular and degenerative cognitive impairment" (EA 2691). Pr. Florence Pasquier is involved in clinical research on cognitive and behavioral disturbances. She has important collaborations on imaging, epidemiology, and basic research. She is a key opinion leader in the field of Alzheimer clinical research.
